Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Client Work

Protox Therapeutics completes US$9 million private placement

Fasken
Reading Time 1 minute read Subscribe
Client

Protox Therapeutics Inc.

On November 29, 2006, Protox Therapeutics Inc. announced that it had successfully completed its previously announced unit offering with the issue of 18,349,500 units at a price of $0.50 per unit for total gross proceeds of $9,174,750. The private placement was led by Jennings Capital Inc. and Canaccord Capital Corporation. Protox is a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other proliferative diseases. Net proceeds from the placement will be used to support the Company's clinical programs and for general corporate purposes. Fasken Martineau advised Protox in this transaction with a team comprised of Iain Mant and Karima Penman.

    Subscribe

    Receive email updates from our team

    Subscribe